Author Archive: Shaira Bhanji

rss feed

Price Discrimination in Pharmaceutical Companies: The Method to the “Madness”

| April 2, 2012 | 1 Comment
Price Discrimination in Pharmaceutical Companies: The Method to the “Madness”

Pharmaceutical companies, or what critics call “big pharma,” are often condemned for charging prices above marginal cost and price discriminating between different countries (calculating each country’s ability to pay). These practices lie at the heart of feuds such as compulsory licensing, a strategy employed by countries to obtain generic drugs. However, the economics of price discrimination demands a closer look.

Continue Reading

Electronic Health Systems: Good for Health, Sanity, and the Environment Too

| November 19, 2011 | 0 Comments
Electronic Health Systems: Good for Health, Sanity, and the Environment Too

Shaira Bhanji Global Health Finance Columnist Paper records, the optimal means by which to capitalize on human error, characterize most current medical information systems. The results are incorrectly prescribed drugs, service delays, and lost files, which together eat about 30-50 percent of U.S. healthcare spending—a hefty $1 trillion per year.[1] Unbeknownst to many, medical errors […]

Continue Reading

Bullying the Boss? Compulsory Licensing for Antiretroviral Drugs in Brazil and Thailand

| October 21, 2011 | 0 Comments
Bullying the Boss? Compulsory Licensing for Antiretroviral Drugs in Brazil and Thailand

By Shaira Bhanji Global Health Finance Columnist Underdeveloped, HIV-burdened regions of the world have the potential to make strides toward better survival outcomes, but they lack key resources. Simple antiretroviral drugs such as Efavirenz and Kaletra have been shown to lower deaths from HIV/AIDS by as much as 84 percent, yet the prices of these […]

Continue Reading